Synuca Therapeutics ApS
Private limited companyCVR 45367282København NActive
Synuca Therapeutics ApS is a private limited company, based in København N, active in research and experimental development on natural sciences and engineering, founded in 2025. Equity was negative at the end of 2025 (−DKK 267k). The company is new and has been registered for 1 years. The latest net result (2025) was a loss of DKK 273k.
Key figures · financial year 2025
What has changed
calculated from recorded figures and datesEmployees
- 1 more employees than a year earlier: 2 (07/2026) against 1 (07/2025).
Management and owners, last 24 months
- New in management: William Brown (director, 30/01/2025), Lasse Reimer (director, 30/01/2025) and Claus Elsborg Olesen (board member, 29/06/2026) (+2).
- New owners registered: Claus Olesen Holding ApS (30/01/2025), Bodd ApS (30/01/2025) and PHJ 2025 Holding ApS (29/05/2026) (+3).
- No longer registered as owner: PHJ 2025 Holding ApS (28/05/2026) and Raul Holding ApS (28/05/2026).
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2025–2025 · amounts in DKK thousand| 2025 | Change | |
|---|---|---|
| Revenue | not stated | – |
| Gross profit | −256 | – |
| Operating profit (EBIT) | −325 | – |
| Profit before tax | −346 | – |
| Net profit | −273 | – |
| Total assets | 345 | – |
| Equity | −267 | – |
| Liabilities | 612 | – |
| Cash and cash equivalents | 267 | – |
| Average number of employees | 1 | – |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresNegative equity
Equity was −DKK 267k at the end of 2025.
How is this calculated?
Equity in the latest annual report is below zero.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
1 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 30/01/2025 – 31/12/2025 | 29/06/2026 | The company | PDF not statedXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 67,234of 69,742 Better than 4% | No. 64,314of 69,964 Better than 8% |
| Same industry and fewer than 20 employees329 companies in the comparison | No. 206of 323 Better than 36% | No. 235of 329 Better than 29% |
| Companies that are founded within the last five years16,662 companies in the comparison | No. 15,925of 16,614 Better than 4% | No. 14,835of 16,661 Better than 11% |
| All companies of type ApS66,508 companies in the comparison | No. 64,413of 66,379 Better than 3% | No. 60,716of 66,505 Better than 9% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineering- Synuca Therapeutics ApS−DKK 256k
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Synuca Therapeutics ApS−DKK 273k
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
- Synuca Therapeutics ApS−DKK 267k
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
- Synuca Therapeutics ApS2
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership Register- Claus Olesen Holding ApS25%
- Bodd ApS25%
- PHJ 2025 Holding ApS15%
- Raul Holding ApS15%
Management
5 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| William Brown | Director | 30/01/2025 |
| Lasse Reimer | Director | 30/01/2025 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Claus Elsborg Olesen | Board member | 29/06/2026 |
| Anker Gunvald Lundemose | Chair of the board | 29/06/2026 |
| Lasse Reimer | Board member | 29/06/2026 |
- Founders
- Claus Olesen Holding ApS, Bodd ApS, PHJ 2025 Holding ApS, Raul Holding ApS
Signing rule: Selskabet tegnes af to direktører i forening eller af den samlede direktion
Address and production units
2 active production unitsOle Maaløes Vej 3
2200 København N
København Municipality · Postcode 2200
Other companies at the address (8)
- BII Holdings A/SOther financial service activities n.e.c.
- Skape Bio ApSResearch and experimental development on natural sciences and engineering
- Agrobiomics ApSResearch and experimental development on natural sciences and engineering
- Tetrakit Technologies ApSResearch and experimental development on natural sciences and engineering
- BioColor ApSResearch and experimental development on natural sciences and engineering
| Production unit | Address | Employees | P number |
|---|---|---|---|
| AU | Høegh-Guldbergs Gade 10, 8000 Aarhus C | 1 | 1031792785 |
| Synuca Therapeutics ApS | Ole Maaløes Vej 3, 2200 København N | 1 | 1031035429 |
Purpose
Selskabets formål er at drive virksomhed med forskning og udarbejdelse af stoffer, herunder til medicinalindustrien, samt enhver i forbindelse hermed stående virksomhed
The purpose is quoted from the register in Danish.
Changes year by year
15 registered events20268 changesmanagement 3 · accounts 1 · ownership 4
- ManagementClaus Elsborg Olesen appointed board member
- ManagementAnker Gunvald Lundemose appointed chair of the board
- ManagementLasse Reimer appointed board member
- AccountsAnnual report for 2025 published
- OwnershipPHJ 2025 Holding ApS registered as owner (15%)
- OwnershipRaul Holding ApS registered as owner (15%)
- OwnershipPHJ 2025 Holding ApS is no longer registered as owner
- OwnershipRaul Holding ApS is no longer registered as owner
20257 changesfounded 1 · management 2 · ownership 4
- FoundedRegistered as Synuca Therapeutics ApS
- ManagementWilliam Brown appointed director
- ManagementLasse Reimer appointed director
- OwnershipPHJ 2025 Holding ApS registered as owner (20%)
- OwnershipRaul Holding ApS registered as owner (20%)
- OwnershipCLAUS OLESEN HOLDING ApS registered as owner (25%)
- OwnershipBODD ApS registered as owner (25%)
Related companies
Same industry in København
- Genmab A/S676 employees
- 3shape A/S518 employees
- Carlsberg A/S107 employees
- IQVIA RDS Denmark A/S100 employees
- Nuevolution A/S100 employees
- Sunshine Enterprise Holding A/S73 employees
Same people in management
- Servier Symphogen A/Svia Anker Gunvald Lundemose
- NMD Pharma A/Svia Claus Elsborg Olesen
- Saniona A/Svia Anker Gunvald Lundemose
- Commit Biologics ApSvia Anker Gunvald Lundemose
- Antag Therapeutics ApSvia Anker Gunvald Lundemose
- Initiator Pharma A/Svia Claus Elsborg Olesen
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.